Table 4.
The oxidation-related predictors of psychopathological symptoms in schizophrenia: multiple models.
| Positive symptoms | R 2 | p-value | β |
|---|---|---|---|
| FRAPxKYN | 24.55% | 0.03 | 0.93 |
| DoI | 0.002 | −0.36 | |
| Negative symptoms | R 2 | p -value | B |
| NoH | 28.73% | 0.006 | 2.33 |
| DITYR | <0.001 | 0.50 | |
| NoHxDITYR | 0.01 | −2.09 | |
| FRAP | 0.04 | −0.20 | |
| CAT | 0.004 | −0.28 | |
| General symptoms | R 2 | p -value | B |
| NoH | 45.78% | 0.03 | 0.28 |
| DoIxKYN | 0.006 | −0.63 | |
| Psychopathological symptoms (total PANSS) | R 2 | p -value | B |
| KYNxNFK | 34.42% | 0.03 | 1.22 |
CAT, catalase; FRAP, ferric reducing ability of plasma; KYN, kynurenine; NFK, N-formylkynurenine; DoI, duration of illness; NoH, number of hospitalization; R2, coefficient of determination; ?, standardized regression coefficients beta; x, interaction between variables.